Literature DB >> 3509282

An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism, and intestinal elimination.

T A Shepard1, R H Reuning.   

Abstract

A relationship between systemic availability and its determinants has been derived for a physiologically realistic model of drug disposition that includes enterohepatic cycling (EHC), gallbladder emptying (with an arbitrary time course), first-pass metabolism to noncycling metabolites, and fecal excretion. Systemic availability (F) has been shown to be determined by the fraction of the dose initially absorbed (f*a), the fraction of the drug excreted into the GI tract that is reabsorbed with each cycle (fa), the hepatic extraction ratio (E), and the fraction of extracted drug that is transported to the gallbladder for EHC (fg) according to the relationship F = f*a(1 - E)/(1 - fafgE) The implications of the above relationship are that (1) systemic availability is dependent on EHC, (2) values of F calculated to be greater than unity cannot be explained simply by the presence of EHC, (3) calculations of E based on the usual expression F = f*a(1 - E) are erroneous for drugs subject to EHC, and (4) a compound that has a high systemic availability and is subject to EHC is not necessarily inefficiently metabolized. The quantitative interrelationship of systemic availability and its determinants is illustrated using a contour plot. Slices through the surface are used to demonstrate that the presence of EHC changes the sensitivity of F to changes in E.

Mesh:

Year:  1987        PMID: 3509282     DOI: 10.1023/a:1016447826075

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  2 in total

1.  Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

2.  Pharmacokinetics and bioavailability of cimetidine in humans.

Authors:  P V Pedersen; R Miller
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

  2 in total
  6 in total

1.  General treatment of the enterohepatic recirculation of drugs and its influence on the area under the plasma level curves, bioavailability, and clearance.

Authors:  J E Peris-Ribera; F Torres-Molina; M C Garcia-Carbonell; J C Aristorena; L Granero
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

2.  An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.

Authors:  Y M Wang; R H Reuning
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

3.  Mean residence time for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; G F Lockwood; L J Aarons; I D Abrahams
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

4.  A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.

Authors:  Toshiya Moriwaki; Hiroyuki Yasui; Akira Yamamoto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

5.  Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac.

Authors:  K Tabata; K Yamaoka; T Fukuyama; T Nakagawa
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

6.  Pharmacokinetics and bioavailability of diclofenac in the rat.

Authors:  J E Peris-Ribera; F Torres-Molina; M C Garcia-Carbonell; J C Aristorena; J M Pla-Delfina
Journal:  J Pharmacokinet Biopharm       Date:  1991-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.